Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post by Razelle Kurzrock on X, adding:
”This Think Tank on Rare Cancers Target Cancer Foundation is ONE of the most impactful meetings in rare cancers. Driven by patient advocates + united by purpose. Academia, pharma (big + small), community leaders, journal editors, societies, and KOLs all in one room with one goal: accelerate rare cancer drug development and save lives.”
Quoting Razelle Kurzrock‘s post:
”Think Tank on rare cancers. Really a wonderful group of people dedicated to helping patients and create new therapeutic paradigms .”
More posts featuring Vivek Subbiah on OncoDaily.